Abstract
Acquired and congenital abnormalities may lead to genitourinary organ damage or loss, requiring eventual reconstruction. Tissue engineering follows the principles of cell transplantation, materials science, and engineering toward the development of biological substitutes that would restore and maintain normal function. Tissue engineering may involve matrices alone, wherein the body's natural ability to regenerate is used to orient or direct new tissue growth, or the use of matrices with cells. Both synthetic and natural biodegradable materials have been used, either alone or as cell delivery vehicles. Tissue engineering has been applied experimentally for the reconstitution of several urologic tissues and organs, including bladder, ureter, urethra, kidney, testis, and genitalia. Fetal applications have also been explored. Recently, several tissue engineering technologies have been used clinically including the use of cells as bulking agents for the treatment of vesicoureteral reflux and incontinence and urethral replacement. Recent progress suggests that engineered genitourinary tissues may have clinical applicability in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 58-73 |
| Number of pages | 16 |
| Journal | American Journal of Transplantation |
| Volume | 4 |
| Issue number | SUPPL. 6 |
| State | Published - Mar 12 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology
Cite this
Tissue engineering for the replacement of organ function in the genitourinary system. / Atala, Anthony.
In: American Journal of Transplantation, Vol. 4, No. SUPPL. 6, 12.03.2004, p. 58-73.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tissue engineering for the replacement of organ function in the genitourinary system
AU - Atala, Anthony
PY - 2004/3/12
Y1 - 2004/3/12
N2 - Acquired and congenital abnormalities may lead to genitourinary organ damage or loss, requiring eventual reconstruction. Tissue engineering follows the principles of cell transplantation, materials science, and engineering toward the development of biological substitutes that would restore and maintain normal function. Tissue engineering may involve matrices alone, wherein the body's natural ability to regenerate is used to orient or direct new tissue growth, or the use of matrices with cells. Both synthetic and natural biodegradable materials have been used, either alone or as cell delivery vehicles. Tissue engineering has been applied experimentally for the reconstitution of several urologic tissues and organs, including bladder, ureter, urethra, kidney, testis, and genitalia. Fetal applications have also been explored. Recently, several tissue engineering technologies have been used clinically including the use of cells as bulking agents for the treatment of vesicoureteral reflux and incontinence and urethral replacement. Recent progress suggests that engineered genitourinary tissues may have clinical applicability in the future.
AB - Acquired and congenital abnormalities may lead to genitourinary organ damage or loss, requiring eventual reconstruction. Tissue engineering follows the principles of cell transplantation, materials science, and engineering toward the development of biological substitutes that would restore and maintain normal function. Tissue engineering may involve matrices alone, wherein the body's natural ability to regenerate is used to orient or direct new tissue growth, or the use of matrices with cells. Both synthetic and natural biodegradable materials have been used, either alone or as cell delivery vehicles. Tissue engineering has been applied experimentally for the reconstitution of several urologic tissues and organs, including bladder, ureter, urethra, kidney, testis, and genitalia. Fetal applications have also been explored. Recently, several tissue engineering technologies have been used clinically including the use of cells as bulking agents for the treatment of vesicoureteral reflux and incontinence and urethral replacement. Recent progress suggests that engineered genitourinary tissues may have clinical applicability in the future.
UR - http://www.scopus.com/inward/record.url?scp=1442338595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1442338595&partnerID=8YFLogxK
M3 - Article
C2 - 14871275
AN - SCOPUS:1442338595
VL - 4
SP - 58
EP - 73
JO - American Journal of Transplantation
JF - American Journal of Transplantation
SN - 1600-6135
IS - SUPPL. 6
ER -